Urology · Austin, TX
NPI
1982601274
Since 2005
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1301 W 38th St Ste 200
Austin, TX, 78705
Phone (512) 477-5905
Groups this clinician bills Medicare through
Medicare paid, 2024
$201K
5,714 services
Medicare patients, 2024
595
Average age 77
Drug cost, 2024
$1.5M
3,744 prescriptions
Company payments, 2025
$740
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffrey N Kocurek was code 99214 (office e&m - established), 885 times for 459 patients. In total Jeffrey N Kocurek billed 5,714 services in 73 codes, and Medicare paid $201K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 885 | 459 | $91.14 | $81K |
| 81003 Clinical Chemistry | Office | 845 | 467 | $2.20 | $1,859 |
| 51798 Ultrasound - Nonspecific | Office | 694 | 380 | $8.60 | $5,966 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 674 | 408 | $12.45 | $8,392 |
| 36415 Venipuncture Blood Collection | Office | 482 | 281 | $8.55 | $4,120 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 352 | 70 | $46.43 | $16K |
| 99213 Office E&M - Established | Office | 211 | 161 | $63.59 | $13K |
| 81001 Clinical Chemistry | Office | 140 | 84 | $3.11 | $435 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 124 | 52 | $37.07 | $4,596 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 112 | 22 | $44.55 | $4,989 |
| 52000 Cystourethroscopy | Office | 61 | 41 | $173.59 | $11K |
| 99204 Office E&M - New | Office | 59 | 59 | $115.25 | $6,800 |
| 51700 Other Organ Systems | Office | 18 | 16 | $58.26 | $1,049 |
| 52601 Prostate Resection | Facility | 11 | 11 | $571.73 | $6,289 |
By year: 2022 $307K for 9,588 services; 2023 $214K for 5,484 services; 2024 $201K for 5,714 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 845 | 467 | $2.20 | $1,859 |
| 36415 Venipuncture Blood Collection | 482 | 281 | $8.55 | $4,120 |
| 81001 Clinical Chemistry | 140 | 84 | $3.11 | $435 |
Medicare prescription drug claims, 2024
In 2024, the drug Jeffrey N Kocurek prescribed most often to Medicare patients was Tamsulosin Hcl, with 788 prescriptions and refills. In total Jeffrey N Kocurek wrote 3,744 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 788 | 1,872 | 214 | $16K |
| Finasteride Generic | 441 | 1,174 | 136 | $6,486 |
| Myrbetriq Mirabegron | 395 | 751 | 126 | $322K |
| Gemtesa Vibegron | 304 | 682 | 101 | $310K |
| Solifenacin Succinate Generic | 214 | 526 | 78 | $9,638 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 210 | 494 | 57 | $4,423 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 162 | 376 | 40 | $3,723 |
| Potassium Citrate Er Potassium Citrate | 119 | 259 | 32 | $8,447 |
| Mirabegron Er Mirabegron | 99 | 277 | 47 | $80K |
| Testosterone Generic | 84 | 107 | 20 | $11K |
| Cefadroxil Generic | 73 | 73 | 66 | $548 |
| Dutasteride Generic | 67 | 146 | 17 | $1,595 |
| Doxycycline Hyclate Generic | 63 | 63 | 55 | $2,719 |
| Desmopressin Acetate Generic | 59 | 113 | 16 | $3,038 |
| Cephalexin Generic | 49 | 78 | 12 | $595 |
Brand drugs: - claims; generic drugs: 2,906 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffrey N Kocurek $740 ($740 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $213.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 9 | $213 |
| Ferring Pharmaceuticals Inc. | 2 | $165 |
| Bluewind Medical | 2 | $90.91 |
| Accord Healthcare, Inc. | 2 | $45.04 |
| Endo USA, Inc. | 2 | $36.2 |
| Urogen Pharma, Inc. URGN | 2 | $35.36 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $35.3 |
| Dendreon Pharmaceuticals LLC | 1 | $34.76 |
| Pfizer Inc. PFE | 2 | $34.24 |
| Janssen Biotech, Inc. JNJ | 1 | $16.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.